Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JBM (Healthcare)'s cash flow for dividends for the
six
months ended in Mar. 2026 was HK$-79.9 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-173.8 Mil.
Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.
JBM (Healthcare)'s quarterly payment of dividends
increased
from Mar. 2025 (HK$-45.2 Mil) to Sep. 2025 (HK$-93.9 Mil) but then
declined
from Sep. 2025 (HK$-93.9 Mil) to Mar. 2026 (HK$-79.9 Mil).
JBM (Healthcare)'s annual payment of dividends
increased
from Mar. 2024 (HK$-52.7 Mil) to Mar. 2025 (HK$-78.7 Mil) and
increased
from Mar. 2025 (HK$-78.7 Mil) to Mar. 2026 (HK$-173.8 Mil).
JBM (Healthcare) Cash Flow for Dividends Related Terms
JBM (Healthcare) Cash Flow for Dividends Historical Data
* Premium members only.
The historical data trend for JBM (Healthcare)'s Cash Flow for Dividends can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JBM (Healthcare) Cash Flow for Dividends Calculation
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-173.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow for Dividends of HK$-173.8 Mil mean?
JBM (Healthcare) (HKSE:02161) has a Cash Flow for Dividends of HK$-173.8 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for JBM (Healthcare) and its competitors.
Is JBM (Healthcare)'s Cash Flow for Dividends too high?
JBM (Healthcare)'s current Cash Flow for Dividends is HK$-173.8 Mil. Overall, JBM (Healthcare) has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JBM (Healthcare)'s Cash Flow for Dividends compare to ZTS?
JBM (Healthcare)'s Cash Flow for Dividends of HK$-173.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for JBM (Healthcare) and its competitors. JBM (Healthcare)'s current Cash Flow for Dividends is HK$-173.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JBM (Healthcare) stock overvalued right now?
Based on GuruFocus' analysis, JBM (Healthcare) (HKSE:02161) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.08, compared to a current price of HK$1.94 — trading 6.7% below its estimated fair value. The current Cash Flow for Dividends is HK$-173.8 Mil. JBM (Healthcare)'s overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For JBM (Healthcare) (HKSE:02161), the current Cash Flow for Dividends is HK$-173.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JBM (Healthcare) (HKSE:02161) Overvalued in 2026?
Based on GuruFocus' analysis, JBM (Healthcare) stock appears to be undervalued.
The current stock price of HK$1.94 is trading 6.7% below its estimated GF Value™ of HK$2.08.
GuruFocus considers JBM (Healthcare) to be Fairly Valued.
Key valuation signals for HKSE:02161:
Cash Flow for Dividends: HK$-173.8 Mil
GF Value™: HK$2.08 vs. price of HK$1.94 (6.7% below fair value)
No single metric tells the full story. See the HKSE:02161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
86GF Score
Get the complete analysis for HKSE:02161
Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02161 has been successfully added to your 
